2000
DOI: 10.1016/s0188-4409(00)00168-5
|View full text |Cite
|
Sign up to set email alerts
|

Induction of Protective Immunity Against Experimental Amebic Abscess of the Liver (EAAL) Using the Monocyte Locomotion Inhibitory Factor (MLIF) Produced by Entamoeba histolytica

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2004
2004
2004
2004

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 2 publications
0
2
0
Order By: Relevance
“…8 weeks), and apparently specific state of protection, as it did not prevent the induction of Listeria monocytogenes abscesses of the liver (ELAL). Previous studies that had revealed a 100% EAAL protection using Freund's adjuvant with or without MLIF, were therefore probably the result of an intense and persistent state of adjuvant‐activated innate immunity that overwhelmed whatever adaptive immunity present (18,19). A pre‐excited state of innate immunity – an improbable event using a MAPS device anyhow – thus appears unlikely as the explanation for the EAAL protection using MLIF–MAPS immunization.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…8 weeks), and apparently specific state of protection, as it did not prevent the induction of Listeria monocytogenes abscesses of the liver (ELAL). Previous studies that had revealed a 100% EAAL protection using Freund's adjuvant with or without MLIF, were therefore probably the result of an intense and persistent state of adjuvant‐activated innate immunity that overwhelmed whatever adaptive immunity present (18,19). A pre‐excited state of innate immunity – an improbable event using a MAPS device anyhow – thus appears unlikely as the explanation for the EAAL protection using MLIF–MAPS immunization.…”
Section: Discussionmentioning
confidence: 99%
“…This led to 100% protection, but so did Freund's adjuvant injections alone. No humoral antibodies to MLIF were found, and delayed skin hypersensitivity was elicited only to the carrier (KLH) (18,19). Instead of such aggressive adjuvant preparations (i.e.…”
Section: Introductionmentioning
confidence: 99%